|
|
Immtech Puts Hold on Clinical Trials of Pafuramidine
publication date: Dec 26, 2007
Immtech Pharma put a hold on its Phase III clinical program for pafuramidine, a treatment for pneumocystis pneumonia (PCP) (an HIV/AIDS related illness) and African sleeping sickness. Immtech is conducting worldwide trials of pafuramidine and recently added a China arm. The drug was given Fast Track status by the SFDA earlier this year. In South African labs, observers noted that trial volunteers had abnormally high liver toxicity readings. More details...
Stock Symbol: (AMEX: IMM)
|
ChinaBio® Events
ChinaBio® Partnering Forum 2012May 23-24, 2012 Suzhou, China >>More events...
Partner Events
 China Healthcare Investment Conference 2012March 13-15, 2012 Shanghai, China Shanghai CEO ConferenceMarch 28-29, 2012 Shanghai, China >>More details...
Other Events
China Pharmaceutical R&D SummitApril 23-26, 2012 Shanghai, China Biosimilars Asia 2012April 23-26, 2012 Shanghai, China Vaccines China 2012April 23-26, 2012 Shanghai, China
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners
![]()
|